Someren-Eind

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial

Retrieved on: 
Thursday, April 27, 2023
Triple-negative breast cancer, Glioblastoma, Human, Therapy, Clinical trial, Cancer, Pharmacokinetics, Transcoding, Breast, RNA, Someren-Eind, Investigational New Drug, Animal, Patient, IRB, Skin, Metastasis, FIH, Liver, FDA, Recurrence, Safety, TTX, Dana, Pharmaceutical industry, Medical imaging, Operation

The planned clinical trial is to evaluate delivery of TransCode’s lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors.

Key Points: 
  • The planned clinical trial is to evaluate delivery of TransCode’s lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors.
  • “We are very pleased to have received IRB Approval for our FIH clinical trial,” said TransCode’s Chief Executive Officer and co-founder, Michael Dudley.
  • “We are pleased that the FDA and IRB have completed their reviews of the Phase 0 clinical trial application and authorized commencement of the trial,” said Susan Duggan, TransCode’s Senior Vice President of Operations.
  • “The FDA authorization and IRB approval to initiate this trial mark the development of TransCode Therapeutics into a clinical-stage oncology company.“

TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Retrieved on: 
Thursday, December 29, 2022
TTX, Cancer, Clinical trial, Investigational New Drug, Pharmacokinetics, Food, Therapy, Drug discovery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transcoding, Breast, TNBC, Toxicology, Glioblastoma, Animal, Metastasis, FIH, Patient, Pharmacology, Someren-Eind, Safety, FDA, IND, Triple-negative breast cancer, Skin, Recurrence, Human, RNA, Liver, Pharmaceutical industry

BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administration (FDA) that it may proceed with its First-in-Human (FIH) Phase 0 clinical trial.

Key Points: 
  • BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S. Food and Drug Administration (FDA) that it may proceed with its First-in-Human (FIH) Phase 0 clinical trial.
  • The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors.
  • “We are pleased to have received written authorization from FDA to proceed with our FIH clinical trial,” said TransCode’s Chief Executive Officer and co-founder, Michael Dudley.
  • The trial could yield critical data regarding therapeutic dose, timing, and potential safety that could inform later stage clinical trials.

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, November 30, 2022
Toxicology, COVID-19, Drug discovery, Recurrence, Glioblastoma, Pharmacokinetics, Food, RNA, Pharmacology, Chemistry, CMC, Cancer, IND, Risk, Safety, Therapy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tumor microenvironment, Annual report, Someren-Eind, TNBC, Liver, Security (finance), Neoplasm, TTX, Metastasis, Intellectual property, Investigational New Drug, PD-L1, Triple-negative breast cancer, Skin, Human, Clinical trial, Animal, Coronavirus, Transcoding, CRISPR, FDA, Breast, Pharmaceutical industry, Vaccine

The planned clinical trial is to evaluate TransCodes lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors.

Key Points: 
  • The planned clinical trial is to evaluate TransCodes lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors.
  • TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors.
  • We are hopeful that the study conducted under the eIND will demonstrate successful delivery of our lead therapeutic candidate to metastatic lesions in patients with advanced solid tumors.
  • Of note, a Phase 0 clinical trial is an exploratory study, conducted under an exploratory Investigational New Drug (eIND) application.

EQS-News: Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Retrieved on: 
Friday, November 11, 2022
MRNA, Immunity, Protein, Health, NYSE, Vaccine, Someren-Eind, NSU, BNTX, Exosome, Food, Factor X, Advertising, Research, Risk, Center, Hyaluronic acid, MicroRNA, Diagnosis, BLA, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Timeline of the COVID-19 pandemic, EVS, PFE, NASDAQ, PPX, Regenerative medicine, Kumasi Centre for Collaborative Research, Johnson & Johnson, Virus, Company, Biologics license application, Science, JNJ, OTCQB, Clinical trial, Patient, BioNTech, Therapy, Pfizer, Infection, Seminal vesicles, Degenerative disease, FDA, Pharmaceutical industry

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Key Points: 
  • Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
  • The company hit a significant milestone in October 2020 when the FDA granted expanded access for patients to be treated with their flagship therapeutic, Zofin.
  • According to Organicell, Zofin is naturally derived and, therefore, only requires 30 patients to complete Phase I/II trials of clinical trials.
  • Phase III trials should require only 250-300 patients, while clinical trials are currently enrolling and anticipated to be completed within 24 months.

TransCode Therapeutics to Present at Sidoti Virtual Investor Conference

Retrieved on: 
Monday, November 7, 2022
RNA, Private Securities Litigation Reform Act, Research, Therapy, Tumor microenvironment, Recurrence, Glioblastoma, Someren-Eind, Cancer, Patent, Breast, Intellectual property, Neoplasm, COVID-19, PD-L1, Annual report, U.S. Securities and Exchange Commission, Coronavirus, TTX, Risk, Transcoding, Technology, Security (finance), CRISPR, Drug discovery, Vaccine, Risk management, Pharmaceutical industry

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

Key Points: 
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.
  • The company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes.
  • Two of the companys other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively.
  • All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma

Retrieved on: 
Wednesday, October 26, 2022
IND, Therapy, Company, Survival, Drug discovery, Clinical trial, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Doctor of Philosophy, Nasdaq, Cancer, Real-time, Disease, PD-L1, Pancreatic tumor, Recurrence, Risk, CEO, Intellectual property, Coronavirus, FIH, Tumor microenvironment, Pancreatic cancer, Breast cancer, Glioblastoma, TTX, RNA, Annual report, Neoplasm, Gene expression, Patient, Technology, Someren-Eind, Breast, GLOBE, COVID-19, CRISPR, Transcoding, Investigational New Drug, Animal, Pancreas, CTO, Mouse, Pharmaceutical industry, Vaccine, Cancer (disambiguation)

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

Key Points: 
  • BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.
  • TransCode Therapeutics evaluated the bioactivity of its lead therapeutic candidate, TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma.
  • In the study, mice bearing human pancreatic tumors implanted in their pancreas were treated once weekly for 10 weeks with TTX-MC138.
  • As with prior studies, we believe the data from this pancreatic cancer study further support advancement of TTX-MC138 into the clinic.

Global Convalescent Plasma Therapy Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Health, General Health, Infection, Journal of Medical Virology, Someren-Eind, GSK, Disease, IND, Immunoglobulin G, Immunoglobulin M, Laboratory, Virology, Severe acute respiratory syndrome coronavirus 2, Immunity, Antibody, Patient, Hospital, CPT, RNA, Mortality, Coronavirus, Collection, MERS, US, Application, Houston Methodist Hospital, Safety, Branches of microbiology, Immunoglobulin A, Journal, CDSCO, Plasma, Mucous membrane, FDA, COVID-19, Pharmaceutical industry

The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.
  • In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate.
  • The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market.
  • The convalescent plasma therapy market consists of sales of convalescent plasma obtained from patients who have recovered from an infection.

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

Retrieved on: 
Thursday, October 13, 2022
Method, U.S. Securities and Exchange Commission, Michigan State University, Someren-Eind, HOXD10, Therapy, Risk, IND, FIH, Animal, Annual report, Neoplasm, Glioblastoma, Patient, Professor, RNA, Frontiers, Investigational New Drug, Security (finance), Entrepreneurship, Cancer, Drinking, Coronavirus, Nasdaq, MRI, Technology, University, Private Securities Litigation Reform Act, Transcoding, Tumor microenvironment, FMC, Company, Drug discovery, Doctor of Philosophy, Breast cancer, Biopsy, Incidence, Breast, CEO, CRISPR, Recurrence, GLOBE, Clinical trial, Intellectual property, Life expectancy, CTO, TTX, PD-L1, Vital signs, COVID-19, Cat, Pharmaceutical industry, Medical imaging, Vaccine, Oncology

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCodes lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer.

Key Points: 
  • BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCodes lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer.
  • The case study was led by Dr. Anna Moore, Professor and Director of the Precision Health Program at Michigan State University and scientific co-founder of TransCode.
  • As with prior studies, we believe the data from this feline case study support advancement of TTX-MC138 into the clinic.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference

Retrieved on: 
Tuesday, September 27, 2022
Therapy, Breast, COVID-19, Risk, CRISPR, Neoplasm, Cancer, Company, TTX, Intellectual property, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Someren-Eind, Technology, Annual report, Coronavirus, RNA, Tumor microenvironment, Research, Security (finance), PD-L1, Glioblastoma, Drug discovery, Patent, Transcoding, Recurrence, Vaccine, Risk management, Pharmaceutical industry

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

Key Points: 
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.
  • The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes.
  • Two of the Companys other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively.
  • All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board

Retrieved on: 
Thursday, September 8, 2022
COVID-19, Breast, Technology, Research, U.S. Securities and Exchange Commission, Genome, GLOBE, Company, Glioblastoma, Risk, Bachelor of Science, PD-L1, Transcoding, Cancer, Oncogene, Beth Israel Deaconess Medical Center, Molecular biology, Department, Nasdaq, RAS, Diabetes, Drug discovery, Intellectual property, Harvard Medical School, Security (finance), RNA, Tumor microenvironment, Therapy, Tufts University School of Medicine, Ageing, Entrepreneurship, LIN28, Recurrence, Patent, CRISPR, Neoplasm, University of Cape Town, Private Securities Litigation Reform Act, CTO, TTX, Someren-Eind, University, MYC, Doctor of Philosophy, Coronavirus, MicroRNA, Single-nucleotide polymorphism, Annual report, Eye, Pharmaceutical industry, Vaccine

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J.

Key Points: 
  • BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J.
  • Slack is one of the most preeminent scientists in the field of small noncoding RNA, commented Zdravka Medarova, PhD , Co-Founder and CTO of TransCode.
  • Slack to our advisory board, commented Michael Dudley , President and Chief Executive Officer of TransCode.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.